Cord blood cells engineered to fight stomach and pancreatic cancers
NCT ID NCT06464965
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This early-phase study tested a new treatment using immune cells from cord blood, modified to target a protein called Claudin18.2 found on some cancer cells. Ten adults with advanced stomach or pancreatic cancer who had no other options received these cells to find the safest dose and check for side effects. The goal was to see if this approach could shrink tumors or slow the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can surgery for stomach or esophageal cancer cloud the mind?
- Can an immunotherapy combo shrink stomach tumors before surgery?